Patents by Inventor Angelika M. Jahreis

Angelika M. Jahreis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY
    Publication number: 20210228597
    Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
    Type: Application
    Filed: December 8, 2020
    Publication date: July 29, 2021
    Applicants: Hoffmann-La Roche Inc., CHUGAI SEIYAKU KABUSHIKI KAISHA, Genentech, Inc.
    Inventors: XIAOPING ZHANG, KIMIO TERAO, ANGELIKA M. JAHREIS, Min Bao
  • Subcutaneously administered anti-IL-6 receptor antibody for treatment of systemic sclerosis
    Patent number: 9539263
    Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: January 10, 2017
    Assignees: Genentech, Inc., Hoffmann-La Roche, Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Xiaoping Zhang, Kimio Terao, Angelika M. Jahreis
  • SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY
    Publication number: 20140056884
    Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
    Type: Application
    Filed: October 24, 2013
    Publication date: February 27, 2014
    Applicants: Genentech, Inc., Chugai Seiyaku Kabushiki Kaisha, Hoffmann-La Roche Inc.
    Inventors: Xiaoping Zhang, Kimio Terao, Angelika M. Jahreis
  • Subcutaneously administered anti-IL-6 receptor antibody
    Patent number: 8580264
    Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: November 12, 2013
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Xiaoping Zhang, Min Bao, Angelika M. Jahreis, Kimio Terao
  • SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY
    Publication number: 20120301460
    Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
    Type: Application
    Filed: November 7, 2011
    Publication date: November 29, 2012
    Applicants: Hoffmann-La Roche, Inc., Genentech, Inc.
    Inventors: Min Bao, Olivier Alfred Harari, Angelika M. Jahreis, Johannes F. Schmidt, Xiaoping Zhang